{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:25:03Z","timestamp":1747164303713,"version":"3.40.5"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdin.2024.03.017","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T13:11:59Z","timestamp":1712409119000},"page":"57-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0207-7402","authenticated-orcid":false,"given":"Kanako","family":"Tsunoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10148","key":"10.1016\/j.jdin.2024.03.017_bib1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jdin.2024.03.017_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15378","article-title":"Risankizmab shows high efficacy and maintenance in improvement of response until week 52","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.jdin.2024.03.017_bib3","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.283","article-title":"Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study","volume":"101","author":"Borroni","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jdin.2024.03.017_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jdin.2024.03.017_bib5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1684\/ejd.2020.3878","article-title":"Real-world data on the use of sekukinumab as treatment for moderate-to-severe psoriasis in Chinese patients","volume":"30","author":"Huang","year":"2020","journal-title":"Eur J Dermatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T03:59:28Z","timestamp":1740887968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":5,"alternative-id":["S2666328724000592"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.03.017","relation":{},"ISSN":["2666-3287"],"issn-type":[{"type":"print","value":"2666-3287"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}